ATE292619T1 - Aminoindanderivate - Google Patents

Aminoindanderivate

Info

Publication number
ATE292619T1
ATE292619T1 AT97953541T AT97953541T ATE292619T1 AT E292619 T1 ATE292619 T1 AT E292619T1 AT 97953541 T AT97953541 T AT 97953541T AT 97953541 T AT97953541 T AT 97953541T AT E292619 T1 ATE292619 T1 AT E292619T1
Authority
AT
Austria
Prior art keywords
dementia
alkyl
compounds
directed
hydrogen
Prior art date
Application number
AT97953541T
Other languages
English (en)
Inventor
Michael Chorev
Tamar Goren
Yacov Herzig
Jeffrey Sterling
Marta Weinstock-Rosin
Moussa B H Youdim
Original Assignee
Teva Pharma
Yissum Res Dev Co
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11985396A external-priority patent/IL119853A0/xx
Priority claimed from IL12051097A external-priority patent/IL120510A0/xx
Application filed by Teva Pharma, Yissum Res Dev Co, Technion Res & Dev Foundation filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE292619T1 publication Critical patent/ATE292619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Centrifugal Separators (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT97953541T 1996-12-18 1997-12-18 Aminoindanderivate ATE292619T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11985396A IL119853A0 (en) 1996-12-18 1996-12-18 Aminoindan derivatives
IL12051097A IL120510A0 (en) 1997-03-24 1997-03-24 Phenylethylamine derivatives
PCT/US1997/024155 WO1998027055A1 (en) 1996-12-18 1997-12-18 Aminoindan derivatives

Publications (1)

Publication Number Publication Date
ATE292619T1 true ATE292619T1 (de) 2005-04-15

Family

ID=26323338

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97953541T ATE292619T1 (de) 1996-12-18 1997-12-18 Aminoindanderivate
AT05002578T ATE377585T1 (de) 1996-12-18 1997-12-18 Aminoindanderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05002578T ATE377585T1 (de) 1996-12-18 1997-12-18 Aminoindanderivate

Country Status (14)

Country Link
US (4) US6303650B1 (de)
EP (2) EP0966435B1 (de)
JP (1) JP4222632B2 (de)
AT (2) ATE292619T1 (de)
AU (1) AU5726898A (de)
CA (1) CA2275425C (de)
DE (2) DE69732984T2 (de)
DK (1) DK0966435T3 (de)
ES (1) ES2241064T3 (de)
HK (2) HK1024462A1 (de)
HU (1) HU229507B1 (de)
IL (1) IL130528A (de)
PT (1) PT966435E (de)
WO (1) WO1998027055A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4222632B2 (ja) * 1996-12-18 2009-02-12 テバ・ファーマシューティカル・インダストリーズ・リミテッド アミノインダン誘導体
US6486178B1 (en) * 1998-06-03 2002-11-26 Nissan Chemical Industries, Ltd. Indane derivatives
EP1242066B1 (de) 1999-10-27 2006-06-28 Teva Pharmaceutical Industries Ltd. Verwendung von 1-aminoindanderivaten zur behandlung der manie in verbindung mit manisch-depressiver erkrankung
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CA2477218A1 (en) * 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
CA2505476C (en) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
CA2547053C (en) * 2003-11-25 2014-05-27 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
EP1574498A1 (de) 2004-02-19 2005-09-14 PPG-Sipsy Verfahren zur Herstellung substituierter alpha-Aminoindanderivate
JP2008507586A (ja) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
WO2006029135A1 (en) * 2004-09-08 2006-03-16 Teva Pharmaceutical Usa, Inc Improved process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates
EP1848415B1 (de) * 2005-02-17 2013-04-03 Teva Pharmaceutical Industries, Ltd. Kombinationstherapie mit glatirameracetat und rasagilin zur behandlung von multipler sklerose
JP2008531546A (ja) * 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
MX2007010392A (es) * 2005-02-24 2007-10-17 Teva Pharma Cristales de ladostigil tratrato, metodos de produccion y composiciones farmaceuticas de los mismos.
CA2600603A1 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Formulations of ladostigil tartrate
EP1888056A4 (de) * 2005-06-01 2008-09-03 Teva Pharma Verwendung von ladostigil zur behandlung von multipler sklerose
WO2006130707A2 (en) * 2005-06-02 2006-12-07 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US7539261B2 (en) * 2005-08-22 2009-05-26 Nec Laboratories America, Inc. Multi-layer coded modulation for non-ergodic block fading channels
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
WO2007038677A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Methods for preparation of ladostigil tartrate crystalline form a1
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
US20070238893A1 (en) * 2005-11-04 2007-10-11 Lee Boulton Asymmetric hydrogenation of acyl enamides
US20070238895A1 (en) * 2005-11-07 2007-10-11 Lee Boulton N-protected aminoindanes and methods of their preparation
CA2630037C (en) * 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
WO2007070425A2 (en) 2005-12-09 2007-06-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of low-dose ladostigil for neuroprotection
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
WO2007098264A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007126898A2 (en) * 2006-03-31 2007-11-08 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of schizophrenia
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016843B1 (ru) 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Таннат разагилина
MX2009006251A (es) * 2006-12-14 2009-10-12 Teva Pharma Base de rasagilina solida cristalina.
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
CA2727019A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
NZ589445A (en) * 2008-06-13 2013-06-28 Teva Pharma Rasagiline for parkinson's disease modification
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
TR201909277T4 (tr) 2010-02-03 2019-07-22 Pharma Two B Ltd Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
JP2013533287A (ja) 2010-07-27 2013-08-22 テバ ファーマシューティカル インダストリーズ リミティド 嗅覚機能不全の処置のためのラサギリンの使用
KR20140084153A (ko) 2011-10-10 2014-07-04 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-메틸-프로파길-아미노인단
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
AU2013217176B2 (en) 2012-02-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil therapy for immunomodulation
EP2884972A4 (de) 2012-08-17 2016-05-11 Teva Pharma Parenterale formulierung von rasagilin

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) 1965-08-17 Chsx c cech
US3123642A (en) 1964-03-03 Indanyl and tetrahydronaphthyl
US2916490A (en) 1959-12-08 Ocjhs
US2982783A (en) 1961-05-02 Amevoevdanes
SE371190B (de) 1972-03-24 1974-11-11 Kabi Ab
US2573645A (en) 1949-05-25 1951-10-30 Smith Kline French Lab N-hydroxyethyl aminoindanes
GB852735A (en) 1956-04-13 1960-11-02 Schering Ag Manufacture of 1-aminoindanes
US3178478A (en) 1961-02-13 1965-04-13 Ciba Geigy Corp 2-amino-5-halo-indanes
US3060091A (en) 1961-02-13 1962-10-23 Ciba Geigy Corp Analgesic composition consisting of morphines and amino-indanes
US3253037A (en) 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US3709996A (en) 1963-08-02 1973-01-09 Aspro Nicholas Ltd Pharmaceutical compositions containing n-cyclopropyl-1-aminoindane compounds and adapted for administration to obtain inhibition of monoamine oxidase enzyme and process
NL6408165A (de) 1964-07-17 1966-01-18
US3308157A (en) 1964-08-07 1967-03-07 Colgate Palmolive Co N-(benzocyclobutene-1-loweralkyl)-carboxylic acid amides
US3637740A (en) 1969-04-21 1972-01-25 Pfizer Aminobenzocycloalkane compounds
US3507962A (en) 1969-05-09 1970-04-21 Thompson Chem Co Hayward Controlling leafminer insects with selected carbamate insecticides,including 3,5-dimethyl-4-dimethylamino-methyl phenyl-n-methylcarbamate
US3704323A (en) 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
NL7011683A (de) 1970-08-07 1972-02-09
US3991207A (en) 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
US3751420A (en) 1971-04-01 1973-08-07 Squibb & Sons Inc Monoolmonoene amines
BE786748A (fr) 1971-07-26 1973-01-26 Basf Ag 1-aminomethyl-indanes-n-substitues
US4029731A (en) 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4134997A (en) 1977-03-01 1979-01-16 University Of Iowa Research Foundation Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
US4096173A (en) 1977-03-28 1978-06-20 Eli Lilly And Company Chlorinated 1-aminoindane N-methyl transferase inhibitors
US4128666A (en) 1977-08-18 1978-12-05 Smithkline Corporation 4 AND 5-Halo substituted 2-indanamine compounds
US4132737A (en) 1978-02-27 1979-01-02 Eli Lilly And Company Trifluoromethyl substituted 1-aminoindanes
US5286747A (en) 1981-05-08 1994-02-15 Per A. E. Carlsson 1-alkyl-2-aminotetralin derivatives
IT1178868B (it) 1983-03-04 1987-09-16 Otsuka Pharma Co Ltd Derivati dell indano e loro sali procedimento per la loro preparazione e composizioni che li contengono
US4529723A (en) 1983-04-29 1985-07-16 William H. Rorer, Inc. Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use
JPS6169747A (ja) 1984-08-31 1986-04-10 Otsuka Pharmaceut Co Ltd ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法
US5242919A (en) 1984-08-31 1993-09-07 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-1H-indene derivatives
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4632939A (en) 1985-03-15 1986-12-30 Eli Lilly And Company Anticonvulsant agents
US4833273A (en) 1986-02-03 1989-05-23 Warner-Lambert Company Process for the resolution of 1-aminoindanes
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US5153225A (en) 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5011995A (en) 1987-07-28 1991-04-30 Ciba-Geigy Corporation Process for the preparation of optically active secondary amines
US4873241A (en) 1988-10-31 1989-10-10 Fisons Corporation 2-amino-N-(2-phenylindan-2-yl)acetamides useful as anti-epileptics
US5225596A (en) 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
CA1335106C (en) 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
JP2725378B2 (ja) * 1989-05-29 1998-03-11 武田薬品工業株式会社 カルバミド酸エステル誘導体
IE902294A1 (en) 1989-07-06 1991-01-16 Abbott Lab Alkynyl amines that regulate cholinergic neurotransmission
US5118704A (en) 1989-08-30 1992-06-02 Whitby Research, Inc. Substituted 2-aminotetralins useful as dopaminergics
US5071875A (en) 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2654104B1 (fr) 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
JPH03176457A (ja) 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
FR2662162B1 (fr) 1990-05-18 1995-01-20 Adir Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
TW197435B (de) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
EP0664291B1 (de) 1992-10-05 2000-07-19 Ube Industries, Ltd. Pyridmidin-derivate
US5350762A (en) 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
GB9315600D0 (en) 1993-07-28 1993-09-08 Smithkline Beecham Plc Compounds
WO1995004713A1 (en) 1993-08-06 1995-02-16 The Upjohn Company 2-aminoindans as selective dopamine d3 ligands
US5516943A (en) 1993-09-14 1996-05-14 Sepracor, Inc. Process for preparing cyclic CIS-1-amino-2-alkanols
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
FR2717175B1 (fr) 1994-03-11 1996-06-14 Adir Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US5646188A (en) 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
JP4222632B2 (ja) * 1996-12-18 2009-02-12 テバ・ファーマシューティカル・インダストリーズ・リミテッド アミノインダン誘導体
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors

Also Published As

Publication number Publication date
DE69738275D1 (de) 2007-12-20
DE69738275T2 (de) 2008-08-28
DE69732984T2 (de) 2006-02-16
EP1535902A1 (de) 2005-06-01
JP4222632B2 (ja) 2009-02-12
DK0966435T3 (da) 2005-08-15
EP0966435A1 (de) 1999-12-29
JP2001506269A (ja) 2001-05-15
US20020188020A1 (en) 2002-12-12
HU229507B1 (en) 2014-01-28
USRE39616E1 (en) 2007-05-08
CA2275425C (en) 2009-08-04
IL130528A (en) 2004-12-15
ES2241064T3 (es) 2005-10-16
CA2275425A1 (en) 1998-06-25
EP0966435A4 (de) 2003-04-16
HUP0101130A2 (hu) 2001-08-28
AU5726898A (en) 1998-07-15
US6303650B1 (en) 2001-10-16
ATE377585T1 (de) 2007-11-15
WO1998027055A1 (en) 1998-06-25
DE69732984D1 (de) 2005-05-12
EP0966435B1 (de) 2005-04-06
US6462222B1 (en) 2002-10-08
HK1076098A1 (en) 2006-01-06
PT966435E (pt) 2005-06-30
US6538025B2 (en) 2003-03-25
EP1535902B1 (de) 2007-11-07
HK1024462A1 (en) 2000-10-13
HUP0101130A3 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE292619T1 (de) Aminoindanderivate
ATE109466T1 (de) Neue derivate des aminopiperidins, aminopyrrolidins und des aminoperhydroazepins, verfahren zur herstellung und diese enthaltende arzneimittel.
BG105781A (en) Piperidine, tetrahydropyridine and piperazine derivatives, their preparartion and use
NO994452D0 (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
ATE173257T1 (de) Heterocyclische verbindungen und ihre herstellung und verwendung
ATE246196T1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
NZ338016A (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
DK0951284T3 (da) Phenylethylminderivater
NO307464B1 (no) Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter
DE69031913D1 (de) Antivirale mittel
HUP0001093A2 (hu) 5-HT2A-antagonista oxazolidinon-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
GR3025318T3 (en) Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[b]indoles and related compounds, intermediates and a process for the preparation thereof and their use as medicaments
LV10235A (lv) Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode
ATE356814T1 (de) Heterozyclische verbindungen, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
ATE261948T1 (de) 2-aminothiazol-kondensierte 2-aminoindane und 2- aminotetraline, sowie deren verwendung
DE69529958D1 (de) Aminoalkyloxime, Verfahren zur dessen Herstellung, ihre Verwendung als Medikamente und Zwischenprodukte
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
DE69610331T2 (de) Neue gylcylanilid-derivate, deren herstellung und deren verwendung zur behandlung von hypercholesterolämie und atherosklerose
DE59308331D1 (de) Verfahren zur Herstellung von 1-unsubstituierten 3-Aminopyrrolen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966435

Country of ref document: EP

REN Ceased due to non-payment of the annual fee